Introduction {#S0001}
============

Because morbidly obese patients have the anatomic and respiratory physiologic changes associated with difficult airways,[@CIT0001] they are commonly considered to have higher risks of difficult facemask ventilation,[@CIT0002] difficult laryngoscopy and intubation,[@CIT0003] failure of supraglottic airway device (SAD) use,[@CIT0004] and difficult surgical airway[@CIT0005] than normal patients.[@CIT0001] In the Fourth National Audit of the Royal Collage of Anesthetists' and the Difficult Airway Society,[@CIT0006],[@CIT0007] the risk of experiencing serious airways complications of morbidly obese patients is at least fourfold more than normal patients. Thus, morbidly obese patients need more elaborate anesthesia and airway management strategies, especially for the selection of anesthetic induction schemes and airway tools.

Awake intubation is generally recommended as the safest strategy for difficult airway management,[@CIT0008] but both the technical challenge and patient refuse limit its extensive application in clinical practice. The available evidence indicates that in morbidly obese patients, SAD can not only be used as an efficient temporary ventilatory tool before tracheal intubation,[@CIT0009] but also may prolong safe apneic period and promote recovery from hypoxemia prior to tracheal intubation.[@CIT0010] Thus, SAD has become a useful alternative for routine or rescue airway management in morbidly obese patients.

Inhalational induction with spontaneous ventilation is one of the recommended methods for difficult airway management.[@CIT0011] Especially, sevoflurane inhalational induction has been widely accepted in clinical practice, as it has some significant advantages, such as minimal irritation to the airway and rapid onset and offset. It has been shown that compared with intravenous propofol induction, sevoflurane inhalational induction can provide a better intubation condition, a lower incidence of apnea under spontaneous ventilation[@CIT0012] and a better hemodynamic stability in obese patients.[@CIT0013] However, ventilatory depression may occur when minimal alveolar concentration (MAC) of sevoflurane is between 1.5 and 2.0 and blood pressure can be decreased by sevoflurane in a dose-dependent manner.[@CIT0014]

Dexmedetomidine (DEX) is a potent α~2~-adrenergic agonist with anesthetic-sparing, sedative, analgesic, sympatholytic and hemodynamic-stabilizing properties and without respiratory depression. These features make DEX a useful and safe adjunct in various applications of clinical anesthesia.[@CIT0015] It has been shown that DEX premedication can significantly improve features of sevoflurane inhalational induction and decrease sevoflurane demand for anesthesia maintenance in normal adult patients.[@CIT0016],[@CIT0017] Furthermore, intranasal or intravenous DEX premedication can significantly decrease sevoflurane end-tidal concentration where 50% (EC~50~) tracheal intubation[@CIT0018] and laryngeal mask airway (LMA) insertion[@CIT0019],[@CIT0020] are successful in children. However, there has been no study assessing the effect of DEX on sevoflurane EC~50~ for successful SAD insertion during inhalational induction with spontaneous breathing in morbidly obese patients. Thus, this study was designed to assess the effect of intravenous DEX on sevoflurane EC~50~ and EC~95~ for successful SAD insertion in morbidly obese patients maintaining a spontaneous breathing.

Patients and methods {#S0002}
====================

The study protocol was approved by the Ethics Committee of the Beijing Friendship Hospital (Ethics Committee number: 2018-P2-079-02) and registered at the Chinese Clinical Trial Registry (<http://www.chictr.org.cn;> registration NO. ChiCTR1800016868). After written informed consents were obtained, 38 morbidly obese patients with a body mass index (BMI) ≥40 kg/m^2^, American Society of Anesthesiologist physical status classification 1 or 2, aged 18--60 years and scheduled for bariatric surgery, were enrolled into this study. The patients with asthma, respiratory tract infection, severe obstructive sleep apnea syndrome, unstable cervical spine, subglottic stenosis, lingual thyroid or tonsillar hypertrophy, allergy or hypersensitive reaction to studied drugs, bradycardia and atrioventricular block, history of gastroesophageal reflux were excluded. By a randomization table, they were allocated to the two groups receiving different treatments: group S, saline was given intravenously, and group D, a bolus dose of DEX 1 μg/kg was administered intravenously over 10 mins, followed by intravenous infusion at a rate of 0.5 μg/kg/h. All tested drugs in both groups were prepared in a 50-mL syringe filled with saline and were marked "4 μg/mL study drug". The intravenous drugs were allocated and infused by one anesthesiologist (first anesthesiologist) who was aware of group allocation.

All the patients were fasted for at least 8 hrs before surgery and received no premedications. After patients arrived in the operating room and an intravenous catheter was placed, standard monitoring including electrocardiogram, noninvasive blood pressure and pulse oxygen saturation (SpO~2~) was applied. During anesthesia induction, bispectral index (BIS), end-tidal concentrations of sevoflurane (ET~sev~), oxygen and carbon dioxide (ETCO~2~), respiratory parameters including tidal volume (TV) and respiratory rate were continuously measured. The lactate ringer's solution was intravenously infused during observation.

The patients were placed at the ramped position (tragus level with sternum).[@CIT0021] Preoxygenation was performed with a 6 L/min fresh oxygen flow through a close facemask and was considered as optimal when the end-tidal concentration of oxygen was 0.9 or more. Then, a bolus dose of DEX 1 μg/kg based on the patient's ideal body weight (IBW) calculated by Miller formula[@CIT0022] and the same volume saline were infused intravenously over 10 mins in groups D and S, respectively. After the bolus doses, DEX was continuously infused intravenously at a rate of 0.5 μg/kg/h in group D and saline was continuously infused intravenously at the same rate as group D in group S. Meanwhile, anesthesia was induced with 5% sevoflurane by a tidal volume breathing technique using a facemask with a 6 L/min fresh oxygen flow after the breathing circuit filled with 5% sevoflurane. During inhalational induction, the jaw was lifted gently for preventing upper airway obstruction and an oropharyngeal airway was used if necessary.

After the beginning of inhalational induction, the patient was asked to open his/her eyes every 5 s by anesthetist's command. Once eyelash reflex disappeared, the inspired concentration of sevoflurane was adjusted to obtain the target ET~sev~, which was set by the first anesthesiologist. According to the previous study,[@CIT0023] the target ET~sev~ of the first patient was set as 2.5% in both groups. The target ET~sev~ was maintained for 5 mins to achieve equilibration. Next, a lubricated BlockBuster^TM^ SAD (Tuo Ren Medical Instrument Co., Ltd., Changyuan, Henan, China) with lidocaine cream was attempted to insert by the second anesthesiologist who was proficient with the use of this device and was blinded to the ET~sev~, BIS value and group allocation. A 4 size of BlockBuster^TM^ SAD was applied for all patients, and the insertion procedure complied with the manufacturer's instructions. The patients' responses to the device insertion were divided into "movement" or "no-movement". Movement was defined if bucking, laryngospasm, coughing, clenching of the teeth, breath holding or gross purposeful limb movement occurred during and within 1 min after the device placement or jaw relaxation was evaluated as poor, ie, a score 3 or 4 of scoring system designed by Muzi et al:[@CIT0024] 1, fully relaxed; 2, mild resistance; 3, tight but could be opened, 4: closed requiring intravenous propofol. If movement was determined, propofol 1 mg/kg based on the IBW was intravenously administered. Only insertion conditions at the first attempt were assessed.

The modified Dixon's up-and-down method (MDUDM)[@CIT0025] is a staircase design in which the next subject's stimulus level is based on the feedback of the previous subject. This staircase design is often used to explore stimulation levels that are not directly measurable to cause a desired feedback. In our study, the target ET~sev~ for next patient depended on previous patient's response, according to the MDUDM with a 0.5% step up (if movement happened in the previous patient) or a downsize (if no movement happened in the previous patient). A crossover point was confirmed once the patient's response was changed from "movement" to "no movement". As the MDUDM commonly requires 6 crossover points,[@CIT0026] patient enrollment was stopped in this study after 6 crossover points had been obtained in each group.

All adverse events during anesthesia induction and SAD insertion were recorded. If apnea occurred and apnea time was over 60 s or SpO~2~ decreased to less than 92% during anesthesia induction, assisted ventilation was performed with a facemask. Hypotension was defined as a decrease in mean artery pressure (MAP) over 20% or non-invasive blood pressure of not more than 90/60 mm Hg; hypertension was defined as an increase in MAP over 20% or non-invasive blood pressure of at least 140/90 mm Hg; bradycardia was diagnosed if HR is below 50 beats/min; tachycardia was diagnosed when HR stays above 100 beats/min. If necessary, ephedrine, urapidil, atropine and esmolol were intravenously injected to treat hypotension, hypertension, bradycardia and tachycardia, respectively.

After the BlockBuster^TM^ SAD was successfully inserted, its position was assessed by a flexible bronchoscope with a 4-mm outer diameter (Karl Storz Endoscopy, Tuttlingen, Germany). Once the adequate position of the device was determined, all patients received intravenous induction with propofol 2 mg/kg and sulfentanil 0.4 μg/kg and rocuronium 0.6 mg/kg according to their IBW. Then, the flexible bronchoscope-guided intubation was performed through the BlockBuster^TM^ SAD.

Data and statistical analysis {#S0003}
=============================

The calculated sevoflurane EC~50~ was acquired by calculating the average of midpoints of all crossover points obtained using MDUDM in each group. Furthermore, the probit regression analysis[@CIT0027] was used to determine sevoflurane end-tidal concentrations where 50% (EC~50~) and 95% (EC~95~) insertions of SAD were successful.

The data are presented as mean ± SD for continuous data and as percentages for categorical data. The comparisons of continuous data between groups were performed using Student's *t*-test. The comparisons of categorical data between groups were done by chi-square test. The SPSS statistical software (version 17.0 SPSS Inc., Chicago, IL, USA) was used for data analysis. A *P-*value of less than 0.05 was considered significant.

Results {#S0004}
=======

The study was performed between July 2018 and November 2018. A total of 41 morbidly obese patients were assessed for eligibility. Of them, 38 were enrolled in the study ([Figure 1](#F0001){ref-type="fig"}). The two groups were comparable with respect to demographical data ([Table 1](#T0001){ref-type="table"}).Table 1Demographic dataGroup SGroup Dn=16n=22Age (yrs)30.2±4.730.4±6.1Sex (M:F)5/116/16BMI (kg/m^2^)45.2±5.644.3±4.0Interincisor distance (cm)7.1±1.56.6±0.6Thyromental distance (cm)8.8±1.18.4±0.9Neck circumference (cm)46.9±4.046.3±4.4Mallampati class II812 III78 IV12Hypertension47Diabetes mellitus813Hyperlipaemia910[^1][^2] Figure 1Flow diagram of morbidly obese patients' recruitment.**Notes:** Group S, saline was given intravenously; group D, a bolus dose of DEX 1 μg/kg was administered intravenously over 10 mins, followed by intravenous DEX infusion at a rate of 0.5 μg/kg/h.

The calculated sevoflurane EC~50~ for successful SAD insertion using MDUDM was 2.92±0.26% and 1.75±0.32% in groups S and D, respectively. The sevoflurane EC~50~ for successful SAD insertion was significantly lower in group D than in group S (*P*\<0.001, [Figure 2](#F0002){ref-type="fig"}).Figure 2Responses of morbidly obese patients in the two groups with the modified Dixon's up-and-down method. Responses of 16 (group S) and 22 (group D) consecutive morbidly obese patients to BlockBuster^TM^ SAD insertion and their ET~sev~ with a modified Dixon's up-and-down method are shown. Arrows indicate the mid-point dose of all independent pairs of patients who manifested cross-over from "movement" (○) to "no movement" (●) response.**Notes:** Group S, saline was given intravenously; group D, a bolus dose of DEX 1 μg/kg was administered intravenously over 10 mins, followed by intravenous DEX infusion at a rate of 0.5 μg/kg/h.**Abbreviations:** D, dexmedetomidine; S, saline; SAD, supraglottic airway device.

The dose--response curves of sevoflurane for successful SAD insertion plotted from the probit regression analysis in the two groups are shown in [Figure 3](#F0003){ref-type="fig"}. The dose--response curve of sevoflurane in group D was significantly shifted to the left compared to group S, indicating a potentiation of DEX on sevoflurane anesthetic efficacy. By the probit regression analysis, EC~50~ and EC~95~ of sevoflurane for successful SAD insertion were 2.81% (95%CI, 2.35--3.29%) and 3.32% (95%CI, 3.02--6.74%) in group S, respectively; 1.59% (95%CI, 1.22--1.90%) and 2.15% (95%CI, 1.86--3.84%) in group D.Figure 3Dose--response curves of sevoflurane for successful insertion of BlockBuster^TM^ SAD in the two groups. The curves plotted from probit regression analysis of individual ET~sev~ and the responses to BlockBuster^TM^ SAD insertion in the morbidly obese patients were shown.**Notes:**Group S, saline was given intravenously; group D, a bolus dose of DEX 1 μg/kg was administered intravenously over 10 mins, followed by intravenous DEX infusion at a rate of 0.5 μg/kg/h.**Abbreviations:** D, dexmedetomidine; S, saline; SAD, supraglottic airway device.

The time of eyelash reflex loss was significantly shorter in group D than in group S (75±23 s *vs* 105±32 s, *P*=0.002). The mean ET~sev~ at eyelash reflex loss were 2.29±0.40% and 2.24±0.44% in groups S and D, respectively (*P*\>0.05). No laryngospasm, aspiration and airway injury during anesthesia induction and device insertion occurred. The flexible bronchoscope-guided intubations through the BlockBuster^TM^ SAD in all patients were successfully completed at the first attempt. SpO~2~ was kept above 98% in all patients throughout the study. There were no significant differences in other adverse events between groups ([Table 2](#T0002){ref-type="table"}). Transient hypotension and bradycardia occurred in some patients, but they recovered rapidly after tracheal intubation without any treatment.Table 2Adverse events related to anesthetic induction and SAD insertionGroup SGroup Dn=16n=22**Anesthetic induction period**Excitatory movements23Coughing11Apnea43Hypotension32Bradycardia11**SADs insertion period**Muzi score\>224Purposeful limb movement26Coughing35Breath holding24[^3][^4]

Discussion {#S0005}
==========

Our study was the first to assess the effect of DEX on sevoflurane EC~50~ for successful SAD insertion during inhalational induction with spontaneous breathing in morbidly obese patients. The results showed that sevoflurane inhalational induction under spontaneous breathing with or without DEX could provide the satisfied conditions for successful SAD insertion. However, a bolus dose of DEX 1 μg/kg followed by a continuous DEX infusion at a rate of 0.5 μg/kg/h could decrease sevoflurane EC~50~ for successful SAD insertion by 40%.

In available literature, there are several studies regarding the effective concentration of inhalational anesthetics for successful SAD insertion in children and normal adult patients.[@CIT0028],[@CIT0029],[@CIT0030] However, there are few studies assessing the effective concentration of inhalational anesthetics for successful SAD insertion in obese patients. In the female patients with normal weight, Kodaka et al[@CIT0031] found that the sevoflurane EC~50~ for successful insertion of LMA Classic (Laryngeal Mask Company, Henley-on-Thames, UK) and LMA Proseal (Laryngeal Mask Company) were 2.36% and 2.82%, respectively. The previous work by Zaballos et al[@CIT0032] in normal adult patients showed that sevoflurane EC~50~ for successful LMA Supreme (Laryngeal Mask Company) insertion was 3.03%. In our study, sevoflurane EC~50~ for successful SAD insertion was 2.81% in group S. Our result is similar to sevoflurane EC~50~ for successful LMA Proseal insertion but is higher than sevoflurane EC~50~ for successful LMA Classic insertion in Kodaka et al' study.[@CIT0031] Furthermore, our result is slightly lower than sevoflurane EC~50~ for successful LMA Supreme insertion in Zaballos et al's study.[@CIT0032] These diverse findings may be attributable to significant differences in the objects and methods among studies. For example, our study subjects are morbidly obese patients and younger than the patients included in other studies.[@CIT0031],[@CIT0032] Our patients were not allowed to receive any premedication, while their patients received midazolam as premedication. In addition, sevoflurane equilibration time during anesthesia induction is significantly shorter in our study (5 mins) than in the above two studies (10 mins). In addition, our study applied a BlockBuster^TM^ SAD, rather than LMA Classic, Supreme or ProSeal used in their study.

It has been shown that MAC of sevoflurane required for maintaining BIS below 50 is significantly increased in the morbidly obese patients compared with the normal adults,[@CIT0033] and an increased BMI is associated with a significantly delayed recovery of protective airway reflexes after sevoflurane anesthesia.[@CIT0034] However, there has been no study determining whether obesity severity can affect sevoflurane anesthetic efficacy during inhalational induction. Recently, Wang et al[@CIT0023],[@CIT0035] showed that when anesthesia was induced by sevoflurane alone and sevoflurane combined with propofol 1 mg/kg in obese patients, sevoflurane EC~50~ for successful insertion of BlockBuster^TM^ SAD were 2.5% and 2.25%, respectively. That is, sevoflurane EC~50~ for successful SAD insertion is higher in our study than in Wang et al's study when alone sevoflurane is used for anesthesia induction.[@CIT0023] It is noted that the average BMI of morbidly obese patients included in our study is significantly larger than that of obese patients included in Wang et al's study[@CIT0023] (45.2±5.6 *vs* 37.2±4.47 kg/m^2^). This suggests that an increased BMI in morbidly obese patients is associated with a decreased sevoflurane anesthetic efficacy, which is in agreement with the previous findings of Zeidan and Mazoit.[@CIT0033] This issue deserves attention and further study.

The available evidence has shown that DEX can reduce EC~50~ of inhalational anesthetics for successful SAD insertion and tracheal intubation in children. For example, He et al[@CIT0018] found that intravenous DEX resulted in a dose-dependent reduction in sevoflurane EC~50~ for excellent intubation conditions in children. Savla et al[@CIT0019] revealed that intranasal DEX 2 μg/kg decreased sevoflurane EC~50~ for LMA classic placement by 21% in children. Yao et al[@CIT0020] showed that intranasal DEX 1 μg/kg and 2 μg/kg in children decreased sevoflurane EC~50~ for flexible LMA (Laryngeal Mask Company) insertion by 20% and 36%, respectively. However, there has been no study assessing the effect of DEX on sevoflurane EC~50~ for SAD insertion and tracheal intubation in adult or obese patients. This study showed that in morbidly obese patients, the use of DEX before anesthesia induction reduced sevoflurane EC~50~ for successful SAD insertion by 40%, without additional adverse effects.

When sevoflurane inhalational induction is performed, the time of eyelash reflex loss is commonly used as induction time.[@CIT0036] Our study showed that the time of eyelash reflex loss was 75±23 s and 105±32 s in groups D and S, respectively. That is, with the dosage regimen used in this study, DEX can shorten the time required for sevoflurane inhalational induction by about 29%. In contrast, Mizrak et al[@CIT0016] demonstrate that when DEX 0.5 μg/kg is intravenously injected 10 mins before anesthesia in normal adult patients, the time required for sevoflurane inhalational induction is reduced by about 75% (15 s *vs* 60 s). However, we believe that their findings do not represent the effect of DEX alone on the time required for sevoflurane inhalational induction, as both fentanyl 1 μg/kg and 50% nitrous oxide are also combined for anesthesia induction in their study. The time of eyelash reflex loss in our group S is comparable with the finding of the Martin-Larrauri et al's study,[@CIT0037] in which time of eyelash reflex with conventional stepwise sevoflurane induction is 118 s.

The incidence of apnea during sevoflurane inhalational induction was 25% and 13.6% in groups S and D, respectively. Group S tended to have a higher incidence of apnea, but a significantly statistical difference between groups was not achieved. As apnea did not occur in the patients with the oropharyngeal airway, moreover, we believe that the occurrence of apnea in our study might be attributable to the upper respiratory obstruction, rather than sevoflurane-induced inhibition of respiratory neurons in the brainstem.[@CIT0038] It has been shown that incidence and duration of apnea during sevoflurane inhalational induction are positively associated with the initial concentration of sevoflurane.[@CIT0039] However, a higher initial concentration of sevoflurane can provide a faster induction time and a shorter second stage of anesthesia during which uncontrolled movements, coughing and breath holding may commonly occur.[@CIT0036] In our study, the choice of a moderate sevoflurane concentration (5%) as the initial concentration for induction is desired to reduce the incidence of apnea while shortening induction time as much as possible.

There are several limitations in our study that deserve attention. First, only morbidly obese patients aged 22--45 years were included. As age can influence the efficacy of sevoflurane,[@CIT0040] our findings may not be extrapolated into morbidly obese patients of other ages. Secondly, only a dosage regimen was used in this study. The available evidence indicates that DEX can enhance the efficacy of sevoflurane and reduce the need of sevoflurane in a dose-dependent mode.[@CIT0008],[@CIT0041] Thus, an important issue that this study cannot answer is whether DEX can result in a dose-dependent potentiation of sevoflurane efficacy for successful SAD insertion when inhalational induction with spontaneous breathing is performed in the morbidly obese patients. Thirdly, an increment of 0.5% sevoflurane was used for MDUDM to determine sevoflurane EC~50~ for successful SAD insertion in our study, even if appropriate increments should be 10% or 15% of the initial concentration or expected MAC value according to Paul and Fisher.[@CIT0042] However, an increment of 0.5% sevoflurane has been used in similar studies,[@CIT0023],[@CIT0035] and this step allows us to compare our results with findings of other studies. Finally, EC~95~ obtained in our study does not represent the optimal anesthesia depth for successful SADs insertion in clinical practice. Thus, further studies to address these issues are needed.

Conclusion {#S0006}
==========

This study demonstrates that when sevoflurane inhalational induction was performed in spontaneously breathing morbidly obese patients, a bolus dose of DEX 1 μg/kg followed by a continuous DEX infusion at a rate of 0.5 μg/kg/h can decrease sevoflurane EC~50~ for successful SAD insertion by 40%.
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[^1]: **Notes:** Group S, saline was given intravenously; group D, a bolus dose of DEX 1 μg/kg was administered intravenously over 10 mins, followed by intravenous DEX infusion at a rate of 0.5 μg/kg/h.

[^2]: **Abbreviations:** BMI, body mass index; D, dexmedetomidine; S, saline.

[^3]: **Notes:**Group S, saline was given intravenously; group D, abolus dose of DEX 1 μg/kg was administered intravenously over 10 mins, followed by intravenous DEX infusion at a rate of 0.5 μg/kg/h.

[^4]: **Abbreviations:** D, dexmedetomidine; S, saline; SAD, supraglottic airway device.
